Giant hemangioma is defined as a cavernous hemangioma larger than 5 cm and represents the large form of the most common benign liver tumor. Histologically it contains endothelium-lined, dilated vascular spaces (cavernous sinusoids) with varying degrees of fibrous stroma, thrombosis, and central scar/fibrosis. It occurs 3-5 times more frequently in women than men, usually diagnosed between ages 30-50. Unlike small hemangiomas, giant hemangiomas may show incomplete enhancement (fill-in), central non-enhancing fibrotic/thrombotic area, mass effect on adjacent structures, and rarely may be associated with Kasabach-Merritt syndrome (consumptive coagulopathy). The typical peripheral nodular enhancement and centripetal fill-in pattern is preserved but complete fill-in may not occur. Marked hyperintensity on T2-weighted MRI ('light-bulb sign') is the most reliable diagnostic finding.
Age Range
30-60
Peak Age
45
Gender
Female predominant
Prevalence
Uncommon
Giant hemangioma is a congenital vascular hamartomatous malformation — not a true neoplasm. Endothelium-lined, dilated vascular spaces (sinusoids) are filled with slow-flowing venous blood. The slow blood flow in these cavernous sinusoids forms the basis of the peripheral nodular enhancement and centripetal (toward center) progressive fill-in pattern on imaging — contrast agent enters from the periphery and fills toward the center due to slow flow. When size exceeds 5 cm, thrombosis, fibrinoid degeneration, and subsequent fibrous scar develop in the central sinusoids; this is the cause of the central hypointense area that does not enhance even in the delayed phase (incomplete fill-in). The marked hyperintensity on T2-weighted MRI reflects the long T2 relaxation time of slow-flowing/stagnant blood within sinusoids — this 'light-bulb sign' is pathognomonic for cavernous hemangioma. The central fibrotic area has low water content and appears relatively hypointense on T2. Because it expresses estrogen receptors, it may grow during pregnancy and hormonal therapy. In Kasabach-Merritt syndrome, stasis and endothelial damage within the giant hemangioma trigger platelet consumption and disseminated intravascular coagulation.
The lesion's marked hyperintensity approaching CSF signal on T2-weighted images — 'light-bulb sign'. Signal increasing with increasing TE (because hemangioma has very long T2) definitively distinguishes this finding from T2 signal of solid tumors. In giant hemangioma, the central fibrotic area appears relatively hypointense on T2, giving a 'target' appearance.
Discontinuous, nodular enhancement foci at the periphery of the lesion in the arterial phase — density equal to or approaching the aorta. Enhancement begins at multiple points along the lesion margins, and these nodules are supplied by surrounding hepatic arterial branches. The central area does not enhance and remains hypodense in this phase. This peripheral nodular enhancement pattern is the most characteristic and diagnostic CT finding of hemangioma. In giant hemangiomas, peripheral enhancement foci may be more prominent and larger.
Report Sentence
A mass >5 cm in the liver demonstrating discontinuous nodular enhancement foci at its periphery approaching aortic density in the arterial phase, consistent with giant hemangioma.
In the delayed phase (5-15 minutes), enhancement progresses from periphery toward center (centripetal fill-in) but complete fill-in does not occur — a non-enhancing hypodense area remains in the central region. This incomplete fill-in reflects the central fibrosis/thrombosis area of the giant hemangioma and distinguishes it from the complete fill-in of small hemangiomas. Enhanced peripheral areas appear isodense or mildly hyperdense to liver parenchyma. Incomplete fill-in pattern is seen in 60-70% of giant hemangiomas.
Report Sentence
Centripetal fill-in pattern is observed in the delayed phase; however, a non-enhancing hypodense central area persists, and this incomplete fill-in is consistent with giant hemangioma.
The lesion shows markedly homogeneous hyperintense signal on T2-weighted images — bright appearance approaching CSF or fluid signal ('light-bulb sign'). Signal intensity increases with increasing TE, and this feature is pathognomonic for hemangioma. In giant hemangiomas, the central fibrotic/thrombotic area may appear relatively hypointense on T2, giving the lesion a 'target-like' appearance. T2 hyperintensity is markedly different from solid malignant lesions.
Report Sentence
The lesion demonstrates marked hyperintensity approaching CSF signal on T2-weighted images consistent with cavernous hemangioma light-bulb sign; central hypointense area is consistent with thrombosis/fibrosis.
The lesion appears hypointense relative to liver parenchyma on T1-weighted images. Focal hyperintense areas may be seen in the central region if thrombosis or hemorrhage is present (T1-shortening effect of methemoglobin). The central area of giant hemangiomas may be heterogeneous — combination of fibrosis (hypointense) and organized thrombus (variable signal). The peripheral sinusoidal component remains homogeneously hypointense.
Report Sentence
The lesion is hypointense relative to liver parenchyma on T1-weighted images with focal hyperintense foci in the central area consistent with thrombosis/hemorrhage.
The lesion appears hyperintense on DWI at low b-values (T2 shine-through effect) but loses signal at high b-values. ADC map shows high ADC values (>2.0 × 10⁻³ mm²/s) — no true diffusion restriction. This reflects facilitated free water diffusion in the sinusoidal spaces of hemangioma. While solid malignant lesions (HCC, metastasis) show true diffusion restriction (low ADC), hemangioma has high ADC — this distinction is supportive for diagnosis.
Report Sentence
T2 shine-through effect is observed in the lesion on DWI with high ADC values on ADC map, no true diffusion restriction detected; this finding is consistent with hemangioma.
Well-defined, predominantly hyperechoic mass >5 cm on B-mode US. Unlike the typical homogeneous hyperechoic appearance of small hemangiomas, giant hemangiomas may show heterogeneous internal echo pattern — central hypoechoic area (fibrosis/thrombosis), cystic areas, and posterior acoustic enhancement. Due to mass effect, compression findings on adjacent hepatic veins and bile ducts may be present. Peripheral vascularity with central avascular area is typical on Doppler.
Report Sentence
Well-defined, predominantly hyperechoic mass >5 cm in the liver on US with central hypoechoic areas consistent with thrombosis/fibrosis; giant hemangioma is considered.
Peripheral discontinuous nodular enhancement after gadolinium contrast injection in the arterial phase — identical to CT pattern. Enhanced peripheral nodules show high signal and progress toward center in portal venous/delayed phases. The advantage of MRI is that diagnostic confidence is very high when evaluated together with T2 hyperintensity. When gadoxetic acid is used, the lesion appears hypointense in the hepatobiliary phase — confirming absence of hepatocytes.
Report Sentence
Characteristic discontinuous nodular enhancement at the periphery of the lesion is observed on MRI after gadolinium injection in the arterial phase, together with T2 hyperintensity supporting the diagnosis of cavernous hemangioma.
Criteria
>5 cm, peripheral nodular enhancement + incomplete centripetal fill-in, T2 hyperintense, central fibrosis/thrombosis area
Distinct Features
Most common form. Incomplete fill-in is the most prominent distinguishing feature. Central scar does not enhance. Usually asymptomatic, may cause mass effect.
Criteria
Extensive hyalinization and fibrosis with narrowing/closure of sinusoidal spaces — conventional enhancement pattern altered
Distinct Features
Atypical enhancement: may show flash-filling or weak enhancement. T2 hyperintensity may be decreased (T2 shortens as fibrosis increases). May mimic malignant lesion. Calcification may be seen on CT.
Criteria
Giant hemangioma + consumptive coagulopathy (thrombocytopenia + microangiopathic hemolytic anemia + hypofibrinogenemia)
Distinct Features
Very rare (1-2%). Emergency clinical situation. Occurs due to stasis and endothelial damage within the hemangioma triggering platelet activation and fibrin deposition. Surgical resection or embolization may be required.
Distinguishing Feature
Small hemangioma (<5 cm) shows complete fill-in in the delayed phase, while giant hemangioma shows incomplete fill-in. Small hemangioma does not contain central fibrosis/thrombosis, shows homogeneous T2 hyperintensity.
Distinguishing Feature
HCC shows heterogeneous arterial enhancement + washout; hemangioma shows peripheral nodular enhancement + centripetal fill-in, no washout. HCC is mildly hyperintense on T2, hemangioma is very bright. HCC shows diffusion restriction, hemangioma does not.
Distinguishing Feature
Cholangiocarcinoma shows progressive central enhancement (desmoplastic reaction — fibrous tissue enhancement from periphery to center); hemangioma shows sinusoidal filling from periphery to center. Cholangiocarcinoma is moderately hyperintense on T2, hemangioma is very bright. Cholangiocarcinoma shows bile duct dilatation and capsular retraction.
Distinguishing Feature
Adenoma may show homogeneous arterial enhancement and washout; hemangioma shows peripheral nodular enhancement. Adenoma is mildly hyperintense on T2, hemangioma is very bright. Adenoma may contain intracellular fat and hemorrhage (opposed-phase signal drop, T1 hyperintensity).
Urgency
routineManagement
surveillanceBiopsy
Not NeededFollow-up
12-monthGiant hemangiomas are generally benign and most do not require treatment. Diagnosis can be definitively made with typical MRI findings (T2 light-bulb sign + peripheral nodular enhancement + incomplete fill-in) — biopsy is contraindicated (bleeding risk). Annual US or MRI follow-up is sufficient in asymptomatic patients. Surgical resection, embolization, or radiotherapy may be considered for symptomatic lesions (pain, compression, Kasabach-Merritt). Close follow-up is recommended in women planning pregnancy due to risk of size increase. Percutaneous biopsy should be avoided due to high bleeding risk.
Most giant hemangiomas are asymptomatic and do not require treatment. Surgical resection or embolization may be considered in symptomatic cases (pain, compression symptoms) or Kasabach-Merritt syndrome. Biopsy is contraindicated (bleeding risk).